Article Text

Download PDFPDF

794 TKM-011, Anti-CD20 antibody confers multi-properties against burkitt’s lymphoma in comparable efficacy to rituximab and obinutuzumab
  1. Jutatip Panaampon and
  2. Seiji Okada
  1. Kumamoto University, Kumamoto, Japan


Background Burkitt’s lymphoma (BL), an aggressive non-Hodgkin B-cell lymphoma needs an intensive chemotherapy regimen for the treatment. Immunotherapy plays significant roles in the treatment of BL. Rituximab (RTX) treatment regimens display the correlation with a positive prognosis. Yet, there is the subset of patients failed to respond to RTX treatment or became the resistance to RTX treatment. Newer generation of monoclonal anti-CD20 antibodies such as Obinutuzumab (OBI) have shown to inhibit B cell malignancies. TKM-011, the novel anti-CD20 antibody that binds to different CD20 epitope has been established. In this study, we studied the efficacy of TKM-011, RTX, and OBI against BL cell lines both in vitro and in vivo.

Methods We screened the antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP) by using the luciferase effector bioassay-based Jurkat cells with the expression of Fc receptor to evaluate ADCC and ADCP activities of RTX, TKM-011, and OBI. Raji and Ramos cell lines were used as the target cells. Flowcytometric analysis was performed to confirm ADCC by using KHYG-1 (CD16-) and N6 (CD16 transduced KHYG-1) NK cell lines. In order to determine ADCP, we generated monocyte-derived macrophages from healthy donors and performed ADCP assay. Moreover, we also tested the efficacy of these antibodies in vivo model by using Raji cells xenografted-immunodeficient mice.

Results TKM-011 exerted ADCC and ADCP activities in the similar levels compared to that of RTX and OBI. Moreover, TKM-011 also showed a potent CDC activity against BL cells. By performing MTT assay, all 3 antibodies presented an induction of cell death. The results of an in vivo experiment demonstrated an equivalent inhibitory level of tumor growth by the three tested antibodies.

Conclusions TKM-011 shows multi-activities against BL cell lines. The efficacy of TKM-011 reaches the level of standard RTX antibody. Considering the different binding epitopes in CD20, TKM-011 can be an alternative antibody therapy for the treatment of BL.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.